No longer confined to cancer centers, skin complications of cancer therapies are now commonly encountered at the community ...

Doctors share what the findings may mean for the future of cancer treatment.

The first two years after completing cancer treatment are considered the most important period for follow-up. Nearly 90 per ...

By targeting three key growth pathways at once, researchers eliminated pancreatic tumors in multiple mouse models and ...

Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...

Hiroshima University researchers developed a three-factor, 12-item, questionnaire-based scale to systematically assess ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

Katie Weimer figured out a way to make regenerative tissue to bring hope to breast cancer survivors around the world. In the lab of her Colorado startup, she is building “scaffolds” from advanced, ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.

In response, Blood Cancer UK, Lymphoma Action, and the stem cell charity Anthony Nolan have formally challenged the decision, citing serious concerns for patients who face "very limited alternatives".